--- title: "Esperion Therapeutics 投资者警报：Kahn Swick & Foti, LLC 正在调查拟议出售 Esperion Therapeutics, Inc.的价格和流程是否合理 - ESPR" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/285095483.md" description: "Kahn Swick & Foti, LLC 正在调查 Esperion Therapeutics, Inc.（纳斯达克代码：ESPR）拟售给 ARCHIMED 基金的事宜。股东将获得每股 3.16 美元的现金，以及潜在的里程碑付款。该公司旨在评估这一报价是否充分反映了公司的价值及其形成过程。感兴趣的各方可以联系 KSF 以获取有关其在此次交易中法律权利的更多信息" datetime: "2026-05-04T16:00:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285095483.md) - [en](https://longbridge.com/en/news/285095483.md) - [zh-HK](https://longbridge.com/zh-HK/news/285095483.md) --- # Esperion Therapeutics 投资者警报：Kahn Swick & Foti, LLC 正在调查拟议出售 Esperion Therapeutics, Inc.的价格和流程是否合理 - ESPR Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. \>\>\>CLICK HERE To Learn More. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-espr/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn Kahn Swick & Foti, LLC Managing Partner Lewis S. Kahn lewis.kahn@ksfcounsel.com 855-768-1857 1100 Poydras St., Suite 960 New Orleans, LA 70163 View source version on businesswire.com: https://www.businesswire.com/news/home/20260504965150/en/ ### 相关股票 - [ESPR.US](https://longbridge.com/zh-CN/quote/ESPR.US.md) ## 相关资讯与研究 - [Esperion 获得德国反垄断机构批准进行合并；股东投票定于 7 月 8 日举行](https://longbridge.com/zh-CN/news/289231651.md) - [关键事实：Esperion 扩展了 2024-25 年的计划；估计下降了 781.6%](https://longbridge.com/zh-CN/news/285820903.md) - [Perion 在 WOO London 2026 上推出程序化数字户外广告新功能](https://longbridge.com/zh-CN/news/288584014.md) - [Monashee Investment Management LLC 收购了 Kymera Therapeutics, Inc. $KYMR 的新股份](https://longbridge.com/zh-CN/news/289577870.md) - [Kymera Therapeutics, Inc. $KYMR 的股票被 Atlas Venture Life Science Advisors LLC 出售](https://longbridge.com/zh-CN/news/289658089.md)